84 related articles for article (PubMed ID: 12538454)
1. Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-gamma, tumor necrosis factor-alpha, IL-6, and IL-8 responses.
Portielje JE; Lamers CH; Kruit WH; Sparreboom A; Bolhuis RL; Stoter G; Huber C; Gratama JW
Clin Cancer Res; 2003 Jan; 9(1):76-83. PubMed ID: 12538454
[TBL] [Abstract][Full Text] [Related]
2. Cytokines and soluble cytokine receptor induction after IL-12 administration in cancer patients.
Haicheur N; Escudier B; Dorval T; Negrier S; De Mulder PH; Dupuy JM; Novick D; Guillot T; Wolf S; Pouillart P; Fridman WH; Tartour E
Clin Exp Immunol; 2000 Jan; 119(1):28-37. PubMed ID: 10606961
[TBL] [Abstract][Full Text] [Related]
3. Association of lymphocyte subsets and cytokines with bone metabolism: a retrospective, cross-sectional study.
Peng C; Yang Q; Kong X; Sun Z; Wang L; Xiao L
BMC Musculoskelet Disord; 2024 Jan; 25(1):43. PubMed ID: 38195444
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneous injection of interleukin 12 induces systemic inflammatory responses in humans: implications for the use of IL-12 as vaccine adjuvant.
Portielje JE; Kruit WH; Eerenberg AJ; Schuler M; Sparreboom A; Lamers CH; Gratama JW; Stoter G; Huber C; Hack CE
Cancer Immunol Immunother; 2005 Jan; 54(1):37-43. PubMed ID: 15693137
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulatory effects of ultra-low-dose interleukin-2 in cancer patients: a phase-IB study.
Lindemann A; Brossart P; Höffken K; Flasshove M; Voliotis D; Diehl V; Hecker G; Wagner H; Mertelsmann R
Cancer Immunol Immunother; 1993 Oct; 37(5):307-15. PubMed ID: 8402734
[TBL] [Abstract][Full Text] [Related]
6. Early immune system alterations in patients with septic shock.
Tang H; Qin S; Li Z; Gao W; Tang M; Dong X
Front Immunol; 2023; 14():1126874. PubMed ID: 36845110
[TBL] [Abstract][Full Text] [Related]
7. IL-12: a promising adjuvant for cancer vaccination.
Portielje JE; Gratama JW; van Ojik HH; Stoter G; Kruit WH
Cancer Immunol Immunother; 2003 Mar; 52(3):133-44. PubMed ID: 12649742
[TBL] [Abstract][Full Text] [Related]
8. Distinctive aspects of the immune status of the Kola Saami and Russians living in the Far North.
Gubkina LV; Samodova AV; Dobrodeeva LK
Am J Hum Biol; 2024 Jan; 36(1):e23969. PubMed ID: 37563854
[TBL] [Abstract][Full Text] [Related]
9. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.
Atkins MB; Robertson MJ; Gordon M; Lotze MT; DeCoste M; DuBois JS; Ritz J; Sandler AB; Edington HD; Garzone PD; Mier JW; Canning CM; Battiato L; Tahara H; Sherman ML
Clin Cancer Res; 1997 Mar; 3(3):409-17. PubMed ID: 9815699
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma.
Motzer RJ; Rakhit A; Schwartz LH; Olencki T; Malone TM; Sandstrom K; Nadeau R; Parmar H; Bukowski R
Clin Cancer Res; 1998 May; 4(5):1183-91. PubMed ID: 9607576
[TBL] [Abstract][Full Text] [Related]
11. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production.
Leonard JP; Sherman ML; Fisher GL; Buchanan LJ; Larsen G; Atkins MB; Sosman JA; Dutcher JP; Vogelzang NJ; Ryan JL
Blood; 1997 Oct; 90(7):2541-8. PubMed ID: 9326219
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma.
Gollob JA; Veenstra KG; Parker RA; Mier JW; McDermott DF; Clancy D; Tutin L; Koon H; Atkins MB
J Clin Oncol; 2003 Jul; 21(13):2564-73. PubMed ID: 12829677
[TBL] [Abstract][Full Text] [Related]
13. A novel naturally occurring tandem promoter in modified vaccinia virus ankara drives very early gene expression and potent immune responses.
Wennier ST; Brinkmann K; Steinhäußer C; Mayländer N; Mnich C; Wielert U; Dirmeier U; Hausmann J; Chaplin P; Steigerwald R
PLoS One; 2013; 8(8):e73511. PubMed ID: 23951355
[TBL] [Abstract][Full Text] [Related]
14. Nanosphere pharmacodynamics improves safety of immunostimulatory cytokine therapy.
Lacinski RA; Dziadowicz SA; Stewart A; Chaharbakhshi E; Akhter H; Pisquiy JJ; Victory JH; Hardham JB; Chew C; Prorock A; Bao Y; Sol-Church K; Hobbs GR; Klein E; Nalesnik MA; Hu G; de Oliveira A; Santiago SP; Lindsey BA
iScience; 2024 Feb; 27(2):108836. PubMed ID: 38303687
[TBL] [Abstract][Full Text] [Related]
15. Lymphodepletion - an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle.
Lickefett B; Chu L; Ortiz-Maldonado V; Warmuth L; Barba P; Doglio M; Henderson D; Hudecek M; Kremer A; Markman J; Nauerth M; Negre H; Sanges C; Staber PB; Tanzi R; Delgado J; Busch DH; Kuball J; Luu M; Jäger U
Front Immunol; 2023; 14():1303935. PubMed ID: 38187393
[TBL] [Abstract][Full Text] [Related]
16. An IL-12-Based Nanocytokine Safely Potentiates Anticancer Immunity through Spatiotemporal Control of Inflammation to Eradicate Advanced Cold Tumors.
Chen P; Yang W; Nagaoka K; Huang GL; Miyazaki T; Hong T; Li S; Igarashi K; Takeda K; Kakimi K; Kataoka K; Cabral H
Adv Sci (Weinh); 2023 Apr; 10(10):e2205139. PubMed ID: 36739605
[TBL] [Abstract][Full Text] [Related]
17. A Phase I Single-Arm Study of Biweekly NHS-IL12 in Patients With Metastatic Solid Tumors.
Gatti-Mays ME; Tschernia NP; Strauss J; Madan RA; Karzai FH; Bilusic M; Redman J; Sater HA; Floudas CS; Toney NJ; Donahue RN; Jochems C; Marté JL; Francis D; McMahon S; Lamping E; Cordes L; Schlom J; Gulley JL
Oncologist; 2023 Apr; 28(4):364-e217. PubMed ID: 36640137
[TBL] [Abstract][Full Text] [Related]
18. IL12 immune therapy clinical trial review: Novel strategies for avoiding CRS-associated cytokines.
Jia Z; Ragoonanan D; Mahadeo KM; Gill J; Gorlick R; Shpal E; Li S
Front Immunol; 2022; 13():952231. PubMed ID: 36203573
[TBL] [Abstract][Full Text] [Related]
19. Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy.
Wang Y; Johnson KCC; Gatti-Mays ME; Li Z
J Hematol Oncol; 2022 Aug; 15(1):118. PubMed ID: 36031601
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, Characterization, and
Lacinski RA; Markel JE; Noore J; Pratt HG; Lindsey BA
J Immunol Res; 2022; 2022():6993187. PubMed ID: 35465347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
